
Taysha Gene Therapies Investor Relations Material
Latest events

Q2 2025
Taysha Gene Therapies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Taysha Gene Therapies Inc
Access all reports
Taysha Gene Therapies Inc. is a biotechnology company focused on developing gene therapies for the treatment of monogenic diseases of the central nervous system. The company leverages its adeno-associated virus (AAV) gene therapy platform to create treatments targeting rare genetic disorders, particularly those affecting the brain and spinal cord. Taysha's pipeline includes therapies aimed at conditions such as neurodegenerative and neurodevelopmental diseases, with a mission to provide life-changing treatments for patients with limited or no therapeutic options. The company is advancing its programs through research, clinical development, and regulatory processes. The company is headquartered in Dallas, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
TSHA
Country
🇺🇸 United States